Physician profile
Kalin Siros
NPI 1558875195
$5,286.88
in general payments reported to CMS, 2019-2025
16 companies · $274 in 2025
The $274 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $509 · 2022: $186 · 2023: $53.98 · 2024: $4,265 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,250 · Food and Beverage: $343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,250.00 |
| Food and Beverage | $342.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $4,250.00 | 2024 | |
| Novo Nordisk INC | $231.14 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $163.13 | 2021-2023 | Seglentis |
| Regeneron Healthcare Solutions, INC. | $122.13 | 2025 | Libtayo |
| Amarin Pharma, INC. | $90.46 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $84.97 | 2021 | |
| Lilly USA, LLC | $74.87 | 2021-2024 | Mounjaro |
| Pfizer INC. | $48.68 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $39.82 | 2021 | |
| Braintree Laboratories, INC. | $38.67 | 2021-2025 | Suflave, Sutab |
| Ethicon US, LLC | $36.68 | 2025 | Vistaseal |
| Janssen Biotech, INC. | $26.21 | 2025 | Rybrevant |
| Aroa Biosurgery Incorporated | $25.98 | 2025 | |
| Integra Lifesciences Corporation | $24.28 | 2025 | Integra, Omnigraft, Surgimend |
| Tersera Therapeutics LLC | $16.23 | 2025 | Xermelo |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kalin Siros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.